COMP <GO>
GRCE vs ANVS // REVENUE GROWTH (YOY)
Grace Therapeutics Inc. (NASDAQ) VS. Annovis Bio Inc. (NYSE) • 15-METRIC TALLY: GRCE 2
— ANVS 2
■ METRIC PARITY
LAST: $1.94 (-3.48%) • MKT CAP: $40.8M
revenue-growth
—
LAST: $1.02 (0.00%) • MKT CAP: $43.5M
revenue-growth
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GRCE VS. ANVS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GRCE | ANVS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -18.90% | -35.00% | +16.10 | GRCE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -21.73% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 1/9 | +1.00 | GRCE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.2 | 51.7 | -5.53 | ANVS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $40.8M | $43.5M | -$2.7M | ANVS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GRCE REV | ANVS REV | GRCE GROSS % | ANVS GROSS % | GRCE FCF | ANVS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$8.9M | -$25.6M |
| FY 2024 | $0 | $0 | — | — | -$14.9M | -$21.9M |
| FY 2023 | $0 | $0 | — | — | -$12.3M | -$40.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GRCE // BETA —
ANVS // BETA —